Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)
about
Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac DeathTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesThe emerging role of biotechnological drugs in the treatment of goutEffect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A ReviewHeart failure with preserved ejection fractionCARD9 as a potential target in cardiovascular diseaseEvasion of inflammasome activation by microbial pathogensInterleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats.Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinraAn expanding role for interleukin-1 blockade from gout to cancer.Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.Clinical predictors of response to anakinra in patients with heart failure.Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial RemodelingPreventing Heart Failure in Inflammatory and Immune DisordersImmune activation and cardiovascular disease in chronic HIV infection.Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis).A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Treating inflammation by blocking interleukin-1 in humans.Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.Predicting therapeutic response in patients with heart failure: the story of C-reactive protein.Inflammatory markers in ST-elevation acute myocardial infarction.Innate immunity and the failing heart: the cytokine hypothesis revisited.A Central Role for Monocyte-Platelet Interactions in Heart Failure.Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.Heart Failure with Preserved Ejection Fraction in Older Adults.Targets for Heart Failure With Preserved Ejection Fraction.Myocardial reverse remodeling: how far can we rewind?After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Interleukin-1 Blockade for the Treatment of Pericarditis.Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction.Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure.Commentary: which comes first, the phoenix or the flame? Reflections on the role of inflammation in patients undergoing lower limb revascularization for peripheral artery disease.Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).Role of cardiac inflammation in right ventricular failure.Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.Early cardiac changes induced by a hypercaloric Western-type diet in "subclinical" obesity.Immunotherapy for cardiovascular disease.
P2860
Q26744359-ACCB270E-7FC7-4733-868C-83E2B1DC98CAQ26799747-F79E596B-9555-4FDF-B881-943761BDD292Q26825459-164765FC-627A-46F6-A1E5-F72B32498C08Q27023183-CC11B3D9-64FF-4634-A873-BE25729F58D8Q27024008-D7E7D24C-D571-4614-8DFC-62C0C5A29821Q28066993-17B3996D-ECFA-468A-9AF4-0713659A825DQ28082757-410BC2CC-2E1D-4158-B870-7042C778881CQ33801215-09210A21-7286-499E-BECD-D4085AC87FD4Q34769627-A0AC74D6-4993-49C1-8AF4-7BA43C1929E2Q34777497-3A27FBA4-5EF8-4441-9715-69CC472EFBE5Q35219001-3234F1A5-B9D4-46BB-BD32-AE85C6618B6EQ35855691-EB787B32-C2BF-4ED9-AA47-86C0ADDA4C0EQ35898868-A68CD2BD-74EA-40BB-B148-02380E06EA6DQ35975645-E9A0BB98-6A98-43F5-817F-C90BEB67D1FAQ35994802-38D80967-D81A-4F0D-B841-34E6191CE398Q36556082-B29A0915-6448-485A-ACC9-67BA897651D0Q37207790-56377619-F563-4738-A590-230015EAFED3Q37361075-0509E864-50C5-4F4C-8F7C-94E2FF45EC3AQ37636664-6A0779DF-23F7-4FE1-B5C7-A100D7F30E68Q38260198-588C3F92-5E1C-4835-A2BD-E6E47EA08A40Q38314153-06BCA249-B7F7-4EEF-B41D-1E4FE01E9652Q38355385-B6563F87-2942-4B70-A97A-CEF12CB3CF3EQ38393039-021D4CA7-7C1B-4885-BC0D-511DF7D9420EQ38620927-3184D6BF-5C51-4F84-B475-A9EB65FF0295Q38665806-B566A63A-636C-4D4D-BCB4-B185FE5ED4FFQ38672337-0CA8B675-9CB5-4693-B557-5561A457E07AQ38688194-22CC68E8-00AD-4133-882B-3A8F2BB5CDB0Q38780883-7CBCDD67-5DDF-49EE-9916-7287A1D9A029Q38807777-0E359478-209D-4DA1-BBBF-1ABE2C8CB48DQ39386445-89C8C43C-FB50-458C-B810-A80807B86222Q41068150-F177BC7D-580C-4AB0-AECF-DC1D85D3EB4DQ41239103-73622D9A-DE16-4FBD-9C40-971C784C12C4Q41785739-2AD79785-8A46-45B0-B14A-4FCEDD349AE6Q45011116-9D573813-B119-4658-923B-08EE71A89479Q45058507-455F3FF6-5640-4F8A-B4B1-DF969FACB286Q45068688-C6970FC6-C97B-4567-A38F-59675AD53115Q45073053-44DDD53F-F8B2-42A1-BB72-D88B0479A9CAQ47096165-1F8E7217-CB37-45A6-BDDB-04126E7F8897Q48255633-39CF2EB0-2F2A-47F0-B103-5DB17C4E5C57Q48532758-9DFF00C2-38DC-40E3-A098-D606DCF0A854
P2860
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effects of interleukin-1 block ...... (from the D-HART pilot study)
@en
type
label
Effects of interleukin-1 block ...... (from the D-HART pilot study)
@en
prefLabel
Effects of interleukin-1 block ...... (from the D-HART pilot study)
@en
P2093
P2860
P50
P1476
Effects of interleukin-1 block ...... (from the D-HART pilot study)
@en
P2093
Antonio Abbate
Arehzo Jahangiri
Benjamin Wallace Van Tassell
Charles Anthony Dinarello
Claudia Oddi
Keyur Bharat Shah
Michael Christopher Kontos
Nayef Antar Abouzaki
Norbert Felix Voelkel
Raquel Appa Falcao
P2860
P304
P356
10.1016/J.AMJCARD.2013.08.047
P407
P577
2013-10-04T00:00:00Z